U.S. Government Holds Patent to Study Which Shows Efficacy of Cannabinoids as Antioxidants with Neuroprotective Abilities

Did You Know?

The U.S. obtained a patent in October of 2003 titled, “Cannabinoids as antioxidants and neuroprotectants.” Assigned to the U.S. as represented by the Department of Health and Human Services. In this patent it claims that, “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism” and that this makes cannabinoids useful in the treatment of a wide variety of oxidation associated diseases including those which are age-related, along with inflammatory and autoimmune diseases. (1)

What are Cannabinoids?

This group of active compounds found in marijuana is also referred to as terpenophenolic chemicals. There are a variety of specific cannabinoid compounds found in cannabis, commonly known as THC or tetrahydrocannabinol. These are the active compounds responsible for marijuana’s therapeutic, and psychoactive abilities.

Although the U.S. government holds this patent, officials still deny the benefits of marijuana to medical patients in most U.S. states and in all states on a federal level. Why is the government so unwilling to green light medical research to further prove the medicinal properties of marijuana? Over half of the American population believe that doctors should be able to prescribe the drug, but still the Federal Government does not recognize our rights as citizens to use it as medication legally even though they hold a patent that acknowledges its benefits as an antioxidant with neuroprotective abilities.


  1. http://www.patentstorm.us/patents/6630507.html

Saftey and Efficacy of Cannabidiol (CBD), a Major Non-Psycotrobic Compound of Cannabis sativa Clinically Tested

Safety and Efficacy of Cannabidiol (CBD), a Major Non-Psycotrobic Compound of Cannabis sativa Clinically Tested

The active components in Cannabis have been studied in hundreds of studies. Recently at the University of Sao Paulo, investigators review over 130 of these papers assessing the impact of these compounds called cannabidiols, or CBDs. CBDs have been shown to have an impact in humans and animals in clinical trials. Studies have shown the effects of multiple cannibinoid extracts were excluded from analysis.

Several studies have suggested that CBDs are well tolerated in humans at high doses. It is also suggested that these compounds are non-toxic in normal cells. Studies also suggest that CBD does not have any impact on physiological functions like heart rate, blood pressure or body temperature, the gastrointestinal tract, or alter psychomotor functions.

A recent study showed safety and side effects of the Cannabis sativa constituent CBD.

Conclusions of the authors reporting the findings say that, “Based on recent advances in cannabinoid administration in humans, controlled CBD may be safe in humans and animals. However, further studies are needed to clarify these reported in vitro and in vivo side effects.”

The therapeutic properties of CBDs are well documented and studies of cannabinoids continue to see what ability they possess for a variety of therapeutic uses like: inflammation, diabetes, epilepsy, cancer, bone density and other health problems. However, CBD is still classified under federal law as a Schedule I drug, prohibited for possession and known to have “no medicinal use for treatment in the United States.”